Working at Novo Nordisk

A successful company

In the early spring of 1923, the first patients were treated with insulin produced by the founders of Novo Nordisk. We have come a long way since then. Breakthroughs such as NovoPen®, NovoSeven® and GLP-1 therapieshave improved the lives of millions of people with diabetes, haemophilia and growth disorders all over the world – and helped to define Novo Nordisk as a world leader in therapeutic proteins.

To ensure we can continue helping people affected by chronic conditions, our business needs to grow both profitably and responsibly. We call this approach the Triple Bottom Line. It means that Novo Nordisk is committed to considering the financial, social and environmental impact of every decision as we work to create value for individuals, society and investors.